Mimotope vaccination – from allergy to cancer

Bibliography

• Lebecque S, Dolecek C, Laffer S, et al. Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1. J Allergy Clin Immunol 1997;99(3):374-84
   PubMedGoogle Scholar
• Yip YL, Smith G, Koch J, et al. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J Immunol 2001;166(8):5271-8
   PubMed Web of Science ®Google Scholar
• Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24(5):758-64
   PubMed Web of Science ®Google Scholar
• Cohen SG, Frankland AW, Dworetzky M. Noon and Freeman on prophylactic inoculation against hay fever. J Allergy Clin Immunol 2003;111(5):1142-50
   PubMed Web of Science ®Google Scholar
• Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341(7):468-75
   PubMed Web of Science ®Google Scholar
• Frew AJ. 25. Immunotherapy of allergic disease. J Allergy Clin Immunol 2003;111(2 Suppl):S712-9
   PubMedGoogle Scholar
• Hafner T, DuBuske L, Kosnik M. Long-term efficacy of venom immunotherapy.Ann Allergy Asthma Immunol 2008;100(2):162-5
   PubMed Web of Science ®Google Scholar
• Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102(4 Pt 1):558-62
   PubMed Web of Science ®Google Scholar
• Mobs C, Slotosch C, Loffler H, et al. Cellular and humoral mechanisms of immune tolerance in immediate-type allergy induced by specific immunotherapy. Int Arch Allergy Immunol 2008;147(3):171-8
   PubMed Web of Science ®Google Scholar
• Gleich GJ, Zimmermann EM, Henderson LL, et al. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 1982;70(4):261-71
   PubMed Web of Science ®Google Scholar
• Gehlhar K, Schlaak M, Becker W, et al. Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy 1999;29(4):497-506
   PubMed Web of Science ®Google Scholar
• Jarolim E, Poulsen LK, Stadler BM, et al. A long-term follow-up study of hyposensitization with immunoblotting. J Allergy Clin Immunol 1990;85(6):996-1004
   PubMed Web of Science ®Google Scholar
• Jensen-Jarolim E, Vogel M, de Weck AL, et al. Anti-IgE autoantibodies mistaken for specific IgG. J Allergy Clin Immunol 1992;89(1 Pt 1):31-43
   PubMed Web of Science ®Google Scholar
• Wachholz PA, Soni NK, Till SJ, et al. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003;112(5):915-22
   PubMed Web of Science ®Google Scholar
• Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007;119(4):780-91
   PubMed Web of Science ®Google Scholar
• Akdis CA, Blesken T, Akdis M, et al. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998;102(1):98-106
   PubMed Web of Science ®Google Scholar
• McHugh SM, Deighton J, Stewart AG, et al. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995;25(9):828-38
   PubMed Web of Science ®Google Scholar
• Roy SR, Sigmon JR, Olivier J, et al. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 2007;99(1):82-6
   PubMed Web of Science ®Google Scholar
• Rezvani M, Bernstein DI. Anaphylactic reactions during immunotherapy. Immunol Allergy Clin North Am 2007;27(2):295-307, viii
   PubMed Web of Science ®Google Scholar
• Jarolim E, Rumpold H, Endler AT, et al. IgE and IgG antibodies of patients with allergy to birch pollen as tools to define the allergen profile of Betula verrucosa. Allergy 1989;44(6):385-95
   PubMed Web of Science ®Google Scholar
• Focke M, Marth K, Flicker S, et al. Heterogeneity of commercial timothy grass pollen extracts. Clin Exp Allergy 2008;38(8):1400-8
   PubMed Web of Science ®Google Scholar
• Tavares B, Rordigues F, Pereira C, et al. Development of new IgE specificities to hymenoptera allergens during venom-specific immunotherapy. Eur Ann Allergy Clin Immunol 2005;37(5):171-6
   PubMedGoogle Scholar
• Moverare R, Elfman L, Vesterinen E, et al. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 2002;57(5):423-30
   PubMed Web of Science ®Google Scholar
• Ball T, Sperr WR, Valent P, et al. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999;29(6):2026-36
   PubMed Web of Science ®Google Scholar
• Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007;119(4):826-30
   PubMed Web of Science ®Google Scholar
• Wachholz PA, Durham SR. Induction of ‘blocking’ IgG antibodies during immunotherapy. Clin Exp Allergy 2003;33(9):1171-4
   PubMed Web of Science ®Google Scholar
• Daeron M, Latour S, Malbec O, et al. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of FcγRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 1995;3(5):635-46
   PubMed Web of Science ®Google Scholar
• Hantusch B, Scholl I, Harwanegg C, et al. Affinity determinations of purified IgE and IgG antibodies against the major pollen allergens Phl p 5a and Bet v 1a: discrepancy between IgE and IgG binding strength. Immunology Lett 2005;97(1):81-9
   PubMed Web of Science ®Google Scholar
• Flicker S, Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol 2003;132(1):13-24
   PubMed Web of Science ®Google Scholar
• Visco V, Dolecek C, Denepoux S, et al. Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J Immunol 1996;157(2):956-62
   PubMed Web of Science ®Google Scholar
• Jensen-Jarolim E, Wiedermann U, Ganglberger E, et al. Allergen mimotopes in food enhance type I allergic reactions in mice. FASEB J 1999;13(12):1586-92
   PubMed Web of Science ®Google Scholar
• Scholl I, Kalkura N, Shedziankova Y, et al. Dimerization of the major birch pollen allergen Bet v 1 is important for its in vivo IgE-cross-linking potential in mice. J Immunol 2005;175(10):6645-50
   PubMed Web of Science ®Google Scholar
• Bredehorst R, David K. What establishes a protein as an allergen? J Chromatogr B Biomed Sci Appl 2001;756(1-2):33-40
   PubMed Web of Science ®Google Scholar
• Mahler M, Bluthner M, Pollard KM. Advances in B-cell epitope analysis of autoantigens in connective tissue diseases. Clin Immunol 2003;107(2):65-79
   PubMed Web of Science ®Google Scholar
• Forster-Waldl E, Riemer AB, Dehof AK, et al. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Mol Immunol 2005;42(3):319-25
   PubMed Web of Science ®Google Scholar
• Christiansen J, Rajasekaran AK. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther 2004;3(11):1493-501
   PubMed Web of Science ®Google Scholar
• Waldmann TA, Morris JC. Development of antibodies and chimeric molecules for cancer immunotherapy. Adv Immunol 2006;90:83-131
   PubMed Web of Science ®Google Scholar
• Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther 2008;8(8):1151-8
   PubMed Web of Science ®Google Scholar
• Newsome BW, Ernstoff MS. The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Br J Clin Pharmacol 2008;66(1):6-19
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244(4905):707-12
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177-82
   PubMed Web of Science ®Google Scholar
• Garrett TP, McKern NM, Lou M, et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol cell 2003;11(2):495-505
   PubMed Web of Science ®Google Scholar
• Sliwkowski MX, Schaefer G, Akita RW, et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994;269(20):14661-5
   PubMed Web of Science ®Google Scholar
• Sliwkowski MX. Ready to partner. Nat Struct Biol 2003;10(3):158-9
   PubMedGoogle Scholar
• Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18(6):977-84
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 2007;357(1):39-51
   PubMed Web of Science ®Google Scholar
• Fendly BM, Winget M, Hudziak RM, et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990;50(5):1550-8
   PubMed Web of Science ®Google Scholar
• Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26(4 Suppl 12):60-70
   PubMed Web of Science ®Google Scholar
• Stancovski I, Hurwitz E, Leitner O, et al. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci USA 1991;88(19):8691-5
   PubMed Web of Science ®Google Scholar
• Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421(6924):756-60
   PubMed Web of Science ®Google Scholar
• Riemer AB, Kraml G, Scheiner O, et al. Matching of trastuzumab (Herceptin®) epitope mimics onto the surface of Her-2/neu–a new method of epitope definition. Mol Immunol 2005;42(9):1121-4
   PubMed Web of Science ®Google Scholar
• Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985;228(4705):1315-7
   PubMed Web of Science ®Google Scholar
• Geysen HM, Rodda SJ, Mason TJ. The delineation of peptides able to mimic assembled epitopes. Ciba Found Symp 1986;119:130-49
   PubMedGoogle Scholar
• Azzazy HM, Highsmith WE Jr. Phage display technology: clinical applications and recent innovations. Clin Biochem 2002;35(6):425-45
   PubMed Web of Science ®Google Scholar
• Felici F, Luzzago A, Folgori A, et al. Mimicking of discontinuous epitopes by phage-displayed peptides, II. Selection of clones recognized by a protective monoclonal antibody against the Bordetella pertussis toxin from phage peptide libraries. Gene 1993;128(1):21-7
   PubMed Web of Science ®Google Scholar
• Luzzago A, Felici F, Tramontano A, et al. Mimicking of discontinuous epitopes by phage-displayed peptides, I. Epitope mapping of human H ferritin using a phage library of constrained peptides. Gene 1993;128(1):51-7
   PubMed Web of Science ®Google Scholar
• Hill HR, Stockley PG. Phage presentation. Mol Microbiol 1996;20(4):685-92
   PubMed Web of Science ®Google Scholar
• Felici F, Castagnoli L, Musacchio A, et al. Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J Mol Biol 1991;222(2):301-10
   PubMed Web of Science ®Google Scholar
• Davies JM, O'Hehir RE, Suphioglu C. Use of phage display technology to investigate allergen-antibody interactions. J Allergy Clin Immunol 2000;105(6 Pt 1):1085-92
   PubMed Web of Science ®Google Scholar
• Parmley SF, Smith GP. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 1988;73(2):305-18
   PubMed Web of Science ®Google Scholar
• Riemer A, Scheiner O, Jensen-Jarolim E. Allergen mimotopes. Methods 2004;32(3):321-7
   PubMed Web of Science ®Google Scholar
• Szalai K, Fuhrmann J, Pavkov T, et al. Mimotopes identify conformational B-cell epitopes on the two major house dust mite allergens Der p 1 and Der p 2. Mol Immunol 2008;45(5):1308-17
   PubMed Web of Science ®Google Scholar
• Mumey BM, Bailey BW, Kirkpatrick B, et al. A new method for mapping discontinuous antibody epitopes to reveal structural features of proteins. J Comput Biol 2003;10(3-4):555-67
   PubMed Web of Science ®Google Scholar
• Halperin I, Wolfson H, Nussinov R. SiteLight: binding-site prediction using phage display libraries. Protein Sci 2003;12(7):1344-59
   PubMed Web of Science ®Google Scholar
• Schreiber A, Humbert M, Benz A, et al. 3D-Epitope-Explorer (3DEX): localization of conformational epitopes within three-dimensional structures of proteins. J Comput Chem 2005;26(9):879-87
   PubMed Web of Science ®Google Scholar
• Enshell-Seijffers D, Denisov D, Groisman B, et al. The mapping and reconstitution of a conformational discontinuous B-cell epitope of HIV-1. J Mol Biol 2003;334(1):87-101
   PubMed Web of Science ®Google Scholar
• Huang YX, Bao YL, Guo SY, et al. Pep-3D-Search: a method for B-cell epitope prediction based on mimotope analysis. BMC bioinformatics 2008;9:538. Published online 16 December 2008, doi:10.1186/1471-2105-9-538
   PubMedGoogle Scholar
• Huang J, Gutteridge A, Honda W, et al. MIMOX: a web tool for phage display based epitope mapping. BMC bioinformatics 2006;7:451. Published online 12 October 2006, doi:10.1186/1471-2105-7-451
   PubMed Web of Science ®Google Scholar
• Ganglberger E, Grunberger K, Sponer B, et al. Allergen mimotopes for 3-dimensional epitope search and induction of antibodies inhibiting human IgE. FASEB J 2000;14(14):2177-84
   PubMed Web of Science ®Google Scholar
• Kohlbacher O, Lenhof HP. BALL–rapid software prototyping in computational molecular biology. Biochemicals algorithms library. Bioinformatics 2000;16(9):815-24
   PubMed Web of Science ®Google Scholar
• Gonnet GH, Cohen MA, Benner SA. Exhaustive matching of the entire protein sequence database. Science 1992;256(5062):1443-5
   PubMed Web of Science ®Google Scholar
• Available from: http://www.rcsb.org/pdb/
   Google Scholar
• Neumann D, Kohlbacher O, Lenhof HP, et al. Lectin–sugar interaction. Calculated versus experimental binding energies. Eur J Biochem FEBS 2002;269(5):1518-24
   PubMedGoogle Scholar
• Partidos CD. Peptide mimotopes as candidate vaccines. Curr Opin Mol Ther 2000;2(1):74-9
   PubMed Web of Science ®Google Scholar
• Wauben MH. Immunological mechanisms involved in experimental peptide immunotherapy of T-cell-mediated diseases. Crit Rev Immunol 2000;20(6):451-69
   PubMed Web of Science ®Google Scholar
• Meola A, Delmastro P, Monaci P, et al. Derivation of vaccines from mimotopes. Immunologic properties of human hepatitis B virus surface antigen mimotopes displayed on filamentous phage. J Immunol 1995;154(7):3162-72
   PubMed Web of Science ®Google Scholar
• Olszewska W, Obeid OE, Steward MW. Protection against measles virus-induced encephalitis by anti-mimotope antibodies: the role of antibody affinity. Virology 2000;272(1):98-105
   PubMed Web of Science ®Google Scholar
• Ho PC, Mutch DA, Winkel KD, et al. Identification of two promiscuous T cell epitopes from tetanus toxin. Eur J Immunol 1990;20(3):477-83
   PubMed Web of Science ®Google Scholar
• Kaumaya PT, Kobs-Conrad S, Seo YH, et al. Peptide vaccines incorporating a ‘promiscuous’ T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity. J Mol Recognit 1993;6(2):81-94
   PubMedGoogle Scholar
• Ganglberger E, Barbara S, Scholl I, et al. Monovalent fusion proteins of IgE mimotopes are safe for therapy of type I allergy. FASEB J 2001;15(13):2524-6
   PubMed Web of Science ®Google Scholar
• Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 1988;85(15):5409-13
   PubMed Web of Science ®Google Scholar
• Bramswig KH, Knittelfelder R, Gruber S, et al. Immunization with mimotopes prevents growth of carcinoembryonic antigen positive tumors in BALB/c mice. Clin Cancer Res 2007;13(21):6501-8
   PubMed Web of Science ®Google Scholar
• Leitner A, Vogel M, Radauer C, et al. A mimotope defined by phage display inhibits IgE binding to the plant panallergen profilin. Eur J Immunol 1998;28(9):2921-7
   PubMed Web of Science ®Google Scholar
• Jensen-Jarolim E, Leitner A, Kalchhauser H, et al. Peptide mimotopes displayed by phage inhibit antibody binding to Bet v 1, the major birch pollen allergen, and induce specific IgG response in mice. FASEB J 1998;12(15):1635-42
   PubMed Web of Science ®Google Scholar
• Hantusch B, Krieger S, Untersmayr E, et al. Mapping of conformational IgE epitopes on Phl p 5a by using mimotopes from a phage display library. J Allergy Clin Immunol 2004;114(6):1294-300
   PubMed Web of Science ®Google Scholar
• Hantusch B, Knittelfelder R, Wallmann J, et al. Internal images: human anti-idiotypic Fab antibodies mimic the IgE epitopes of grass pollen allergen Phl p 5a. Mol Immunol 2006;43(14):2180-7
   PubMed Web of Science ®Google Scholar
• Wallmann J, Proell M, Stepanoska T, et al. A mimotope gene encoding the major IgE epitope of allergen Phl p 5 for epitope-specific immunization. Immunol Lett 2009;122(1):68-75
   PubMed Web of Science ®Google Scholar
• Untersmayr E, Szalai K, Riemer AB, et al. Mimotopes identify conformational epitopes on parvalbumin, the major fish allergen. Mol Immunol 2006;43(9):1454-61
   PubMed Web of Science ®Google Scholar
• Furmonaviciene R, Tighe PJ, Clark MR, et al. The use of phage-peptide libraries to define the epitope specificity of a mouse monoclonal anti-Der p 1 antibody representative of a major component of the human immunoglobulin E anti-Der p 1 response. Clin Exp Allergy 1999;29(11):1563-71
   PubMed Web of Science ®Google Scholar
• Pacios LF, Tordesillas L, Cuesta-Herranz J, et al. Mimotope mapping as a complementary strategy to define allergen IgE-epitopes: peach Pru p 3 allergen as a model. Mol Immunol 2008;45(8):2269-76
   PubMed Web of Science ®Google Scholar
• van Neerven RJ. The role of allergen-specific T cells in the allergic immune response: relevance to allergy vaccination. Allergy 1999;54(6):552-61
   PubMed Web of Science ®Google Scholar
• Scholl I, Wiedermann U, Forster-Waldl E, et al. Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1, induces B cell responses to the natural antigen using bystander T cell help. Clin Exp Allergy 2002;32(11):1583-8
   PubMedGoogle Scholar
• Popkov M, Sidrac-ghali S, Alakhov V, et al. Epitope-specific antibody response to HT-1080 fibrosarcoma cells by mimotope immunization. Clin Cancer Res 2000;6(9):3629-35
   PubMed Web of Science ®Google Scholar
• Qiu J, Luo P, Wasmund K, et al. Towards the development of peptide mimotopes of carbohydrate antigens as cancer vaccines. Hybridoma 1999;18(1):103-12
   PubMed Web of Science ®Google Scholar
• Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human–mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998;16(6):2169-80
   PubMed Web of Science ®Google Scholar
• Riemer AB, Forster-Waldl E, Bramswig KH, et al. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Eur J Immunol 2006;36(5):1267-74
   PubMed Web of Science ®Google Scholar
• Fest S, Huebener N, Weixler S, et al. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res 2006;66(21):10567-75
   PubMed Web of Science ®Google Scholar
• Bolesta E, Kowalczyk A, Wierzbicki A, et al. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res 2005;65(8):3410-8
   PubMed Web of Science ®Google Scholar
• Wagner S, Hafner C, Allwardt D, et al. Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J Immunol 2005;174(2):976-82
   PubMed Web of Science ®Google Scholar
• Riemer AB, Hantusch B, Sponer B, et al. High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells. Cancer Immunol Immunother 2005;54(7):677-84
   PubMed Web of Science ®Google Scholar
• Luo W, Ko E, Hsu JC, et al. Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J Immunol 2006;176(10):6046-54
   PubMed Web of Science ®Google Scholar
• Hafner C, Wagner S, Jasinska J, et al. Epitope-specific antibody response to Mel-CAM induced by mimotope immunization. J Invest Dermatol 2005;124(1):125-31
   PubMed Web of Science ®Google Scholar
• Bender H, Grapow M, Schomburg A, et al. Effects of diagnostic application of monoclonal antibody on survival in melanoma patients. Hybridoma 1997;16(1):65-8
   PubMed Web of Science ®Google Scholar
• Mittelman A, Chen ZJ, Liu CC, et al. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Cancer Res 1994;54(2):415-21
   PubMed Web of Science ®Google Scholar
• Wagner S, Krepler C, Allwardt D, et al. Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine. Clin Cancer Res 2008;14(24):8178-83
   PubMed Web of Science ®Google Scholar
• Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(Suppl 4):S3-8
   PubMed Web of Science ®Google Scholar
• Vaisman N, Nissim A, Klapper LN, et al. Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library. Immunol Lett 2000;75(1):61-7
   PubMed Web of Science ®Google Scholar
• Riemer AB, Klinger M, Wagner S, et al. Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol 2004;173(1):394-401
   PubMed Web of Science ®Google Scholar
• Riemer AB, Kurz H, Klinger M, et al. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Nat Cancer Inst 2005;97(22):1663-70
   PubMed Web of Science ®Google Scholar
• Dakappagari NK, Douglas DB, Triozzi PL, et al. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 2000;60(14):3782-9
   PubMed Web of Science ®Google Scholar
• Dakappagari NK, Pyles J, Parihar R, et al. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol 2003;170(8):4242-53
   PubMed Web of Science ®Google Scholar
• Jasinska J, Wagner S, Radauer C, et al. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Int J Cancer 2003;107(6):976-83
   PubMed Web of Science ®Google Scholar
• Wagner S, Jasinska J, Breiteneder H, et al. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Res Treat 2007;106(1):29-38
   PubMed Web of Science ®Google Scholar
• Countouriotis A, Moore TB, Sakamoto KM. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem cells 2002;20(3):215-29
   PubMed Web of Science ®Google Scholar
• Li M, Yan Z, Han W, et al. Mimotope vaccination for epitope-specific induction of anti-CD20 antibodies. Cell Immunol 2006;239(2):136-43
   PubMed Web of Science ®Google Scholar
• Turner MC, Chen Y, Krewski D, et al. Cancer mortality among US men and women with asthma and hay fever. Am J Epidemiol 2005;162(3):212-21
   PubMed Web of Science ®Google Scholar
• Neuchrist C, Kornfehl J, Grasl M, et al. Distribution of immunoglobulins in squamous cell carcinoma of the head and neck. Int Arch Allergy Immunol 1994;104(1):97-100
   PubMed Web of Science ®Google Scholar
• Fu SL, Pierre J, Smith-Norowitz TA, et al. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin Exp Immunol 2008;153(3):401-9
   PubMed Web of Science ®Google Scholar
• Nagy E, Berczi I, Sehon AH. Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus. Cancer Immunol Immunother 1991;34(1):63-9
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Darcy PK, Trapani JA, et al. Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth. Oncol Res 1998;10(3):133-42
   PubMed Web of Science ®Google Scholar
• Gould HJ, Mackay GA, Karagiannis SN, et al. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol 1999;29(11):3527-37
   PubMed Web of Science ®Google Scholar
• Karagiannis P, Singer J, Hunt J, et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother published online 22 October 2008, doi: 10.1007/s00262-008-0607-1
   Google Scholar
• Jensen-Jarolim E, Achatz G, Turner MC, et al. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy 2008;63(10):1255-66
   PubMed Web of Science ®Google Scholar
• Untersmayr E, Jensen-Jarolim E. The role of protein digestibility and antacids on food allergy outcomes. J Allergy Clin Immunol 2008;121(6):1301-8; quiz 9-10
   PubMed Web of Science ®Google Scholar
• Mekori YA, Metcalfe DD. Mast cells in innate immunity. Immunol Rev 2000;173:131-40
   PubMed Web of Science ®Google Scholar
• Riemer AB, Untersmayr E, Knittelfelder R, et al. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res 2007;67(7):3406-11
   PubMed Web of Science ®Google Scholar
• Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol 1994;15(1):42-52
   PubMed Web of Science ®Google Scholar
• Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Phys 2003;195(3):346-55
   PubMed Web of Science ®Google Scholar
• Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 2002;3(11):999-1005
   PubMed Web of Science ®Google Scholar
• Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12(5):601-9
   PubMed Web of Science ®Google Scholar